---
layout: minimal-medicine
title: Lutetium Lu 177 dotatate
---

# Lutetium Lu 177 dotatate
### Generic Name
Lutetium Lu 177 dotatate

### Usage

Lutetium Lu 177 dotatate is a radiopharmaceutical used in Peptide Receptor Radionuclide Therapy (PRRT). Its primary use is in the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).  This includes tumors originating in the foregut, midgut, and hindgut.  It's a targeted therapy, meaning it specifically targets the tumor cells expressing somatostatin receptors, minimizing damage to healthy tissue.  Currently, there are no established uses in pediatric populations.

### Dosage

**Adult Dosage (GEP-NETs):** The typical dosage is 7.4 GBq (200 mCi) administered intravenously (IV) every 8 weeks for a total of four doses.  This regimen requires premedication and concomitant medications (described in the General Considerations section).

**Pediatric Dosage:**  The safety and efficacy of Lutetium Lu 177 dotatate have not been established in children.

**Dosage Adjustments:**  Dose adjustments are necessary based on several factors, including pre-existing or treatment-emergent hepatic or renal impairment, and hematologic toxicity.  Specific guidelines for dose reductions and withholding of treatment are provided in the manufacturer's labeling.  Always consult the prescribing information for the most current and detailed recommendations.  Generally,  hepatic or renal impairment, anemia, neutropenia, and thrombocytopenia may necessitate dose reductions or treatment interruption.

### Side Effects

**Common Side Effects (occurring in >10% of patients):**

* Cardiovascular: Flushing, hypertension, peripheral edema
* Dermatologic: Alopecia (hair loss)
* Endocrine & Metabolic: Hyperglycemia, hyperkalemia, hypernatremia, hyperuricemia, hypocalcemia, hypoglycemia, hypokalemia, increased gamma-glutamyl transferase
* Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, nausea, vomiting
* Hematologic & Oncologic: Anemia, leukopenia, lymphocytopenia, neutropenia, thrombocytopenia
* Hepatic: Increased serum ALT, ALP, AST, and bilirubin levels
* Nervous System: Anxiety, dizziness, fatigue, headache
* Neuromuscular & Skeletal: Back pain, limb pain
* Renal: Increased serum creatinine, renal failure
* Respiratory: Cough


**Less Common but Serious Side Effects (occurring in 1-10% of patients or less):**

* Cardiovascular: Atrial fibrillation
* Gastrointestinal: Constipation, dysgeusia (altered taste)
* Genitourinary: Urotoxicity
* Hematologic & Oncologic: Myelodysplastic syndrome
* Neuromuscular & Skeletal: Myalgia (muscle pain), neck pain
* Other: Fever

**Important Note:** This is not an exhaustive list.  Any new or worsening symptoms should be reported to a healthcare provider immediately.


### How it Works

Lutetium Lu 177 dotatate is a type of targeted therapy called peptide receptor radionuclide therapy (PRRT).  It works by combining a radioactive isotope (Lutetium Lu 177) with a somatostatin analog (dotatate).  Somatostatin analogs bind to specific receptors (somatostatin receptors, particularly subtype 2) found on the surface of many GEP-NET cells.  Once the Lutetium Lu 177 dotatate binds to these receptors, the radioactive isotope emits beta particles, which damage and destroy the tumor cells.  The targeted nature of this therapy helps to minimize harm to surrounding healthy tissue.

### Precautions

* **Hypersensitivity:** Lutetium Lu 177 dotatate is contraindicated in patients with known hypersensitivity to the drug or its components.
* **Bone Marrow Suppression:**  There's an increased risk of bone marrow suppression, so regular blood counts are essential.
* **Gastrointestinal Toxicity:**  Patients should be monitored for gastrointestinal symptoms.
* **Hepatotoxicity & Renal Toxicity:**  Close monitoring of liver and kidney function is necessary, with appropriate dose adjustments as needed.
* **Neuroendocrine Hormonal Crisis:** Although rare, this serious complication can occur.  Patients need to be monitored closely.
* **Pregnancy and Breastfeeding:**  Women of childbearing age should use effective contraception during and for several months after treatment.  Lutetium Lu 177 dotatate should not be used during pregnancy due to the risk of fetal harm. Breastfeeding is not recommended during treatment and for a specified period afterward.
* **Interactions:**  Other somatostatin analogs may interfere with Lutetium Lu 177 dotatate's effectiveness.  Inform your doctor of all medications you are taking.


### FAQs

* **Q: How is Lutetium Lu 177 dotatate administered?** A: It's given intravenously (IV) as an infusion, not a bolus injection.  Specific infusion procedures are outlined in the prescribing information.

* **Q: How long does treatment last?** A: Typically, it involves four doses given over several months, with each dose administered every eight weeks.

* **Q: What are the long-term effects?** A: Long-term effects are variable and depend on individual responses. Ongoing monitoring is crucial to detect any late-onset side effects.

* **Q: How is Lutetium Lu 177 dotatate stored?** A: Storage instructions are provided by the manufacturer and should be followed carefully.

* **Q: What precautions should be taken after treatment?** A:  Follow your healthcare provider's instructions regarding follow-up appointments, monitoring of side effects, and lifestyle adjustments.  Special precautions for handling body fluids may also be necessary due to the radioactive nature of the drug.

**Disclaimer:** This information is for general knowledge and should not be considered medical advice.  Always consult with a healthcare professional for diagnosis and treatment of any medical condition.  Refer to the complete prescribing information for the most up-to-date and detailed instructions.
